274 related articles for article (PubMed ID: 22045752)
1. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation.
Mainz JG; Michl R; Pfister W; Beck JF
Am J Respir Crit Care Med; 2011 Nov; 184(9):1089-90. PubMed ID: 22045752
[No Abstract] [Full Text] [Related]
2. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.
Berlana D; Llop JM; Manresa F; Jódar R
Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493
[TBL] [Abstract][Full Text] [Related]
3. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
4. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
Woodward TC; Brown R; Sacco P; Zhang J
J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
[TBL] [Abstract][Full Text] [Related]
5. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
Ratjen F; Döring G; Nikolaizik WH
Lancet; 2001 Sep; 358(9286):983-4. PubMed ID: 11583754
[TBL] [Abstract][Full Text] [Related]
6. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309
[No Abstract] [Full Text] [Related]
7. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of a new nasal spray formulation containing hyaluronate and tobramycin in cystic fibrosis patients with bacterial rhinosinusitis.
Di Cicco M; Alicandro G; Claut L; Cariani L; Luca N; Defilippi G; Costantini D; Colombo C
J Cyst Fibros; 2014 Jul; 13(4):455-60. PubMed ID: 24656944
[TBL] [Abstract][Full Text] [Related]
9. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Griese M; Müller I; Reinhardt D
Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
[TBL] [Abstract][Full Text] [Related]
10. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
Farinde A
Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292
[No Abstract] [Full Text] [Related]
11. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of sinus surgery and adjuvant therapy in cystic fibrosis patients - can chronic lung infections be postponed?
Aanaes K; Johansen HK; Skov M; Buchvald FF; Hjuler T; Pressler T; Hoiby N; Nielsen KG; von Buchwald C
Rhinology; 2013 Sep; 51(3):222-30. PubMed ID: 23943728
[TBL] [Abstract][Full Text] [Related]
13. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
[No Abstract] [Full Text] [Related]
14. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
[TBL] [Abstract][Full Text] [Related]
15. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
Pierart F
Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
[TBL] [Abstract][Full Text] [Related]
16. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
17. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
[TBL] [Abstract][Full Text] [Related]
18. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Somayaji R; Parkins MD
Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
[TBL] [Abstract][Full Text] [Related]
19. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
McCrae WM; Raeburn JA; Hanson EJ
J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
Moore JE; Maeda Y; Goldsmith CE; Rendall JC; Elborn JS
J Cyst Fibros; 2010 May; 9(3):237-8. PubMed ID: 20378421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
